Blueprint Medicines Corp [NASDAQ: BPMC] jumped around 0.78 points on Thursday, while shares priced at $129.33 at the close of the session, up 0.61%.
Blueprint Medicines Corp stock is now 11.18% up from its year-to-date (YTD) trading value. BPMC Stock saw the intraday high of $129.49 and lowest of $129.23 per share. The company’s 52-week high price is 128.78, which means current price is +77.07% above from all time high which was touched on 07/10/25.
Compared to the average trading volume of 3.05M shares, BPMC reached a trading volume of 5983607 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Blueprint Medicines Corp [BPMC]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BPMC shares is $130.60 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BPMC stock is a recommendation set at 2.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wedbush have made an estimate for Blueprint Medicines Corp shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on June 02, 2025. While these analysts kept the previous recommendation, Morgan Stanley raised their target price to Equal-Weight. The new note on the price target was released on March 20, 2025, representing the official price target for Blueprint Medicines Corp stock.
The Price to Book ratio for the last quarter was 24.41, with the Price to Cash per share for the same quarter was set at 8.91.
How has BPMC stock performed recently?
Blueprint Medicines Corp [BPMC] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.88. With this latest performance, BPMC shares gained by 1.06% in over the last four-week period, additionally plugging by 44.44% over the last 6 months – not to mention a rise of 48.28% in the past year of trading.
Blueprint Medicines Corp [BPMC]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Blueprint Medicines Corp [BPMC] shares currently have an operating margin of -31.01% and a Gross Margin at 93.65%. Blueprint Medicines Corp’s Net Margin is presently recorded at -27.70%.
Return on Equity for this stock declined to -13.94%, with Return on Assets sitting at -13.94%.
Insider trade positions for Blueprint Medicines Corp [BPMC]
There are presently around $109.19%, or 110.16% of BPMC stock, in the hands of institutional investors. The top three institutional holders of BPMC stocks are: BLACKROCK INC. with ownership of 6.65 million shares, which is approximately 10.5758%. VANGUARD GROUP INC, holding 6.54 million shares of the stock with an approximate value of $$704.72 million in BPMC stocks shares; and VANGUARD GROUP INC, currently with $$633.03 million in BPMC stock with ownership which is approximately 9.3445%.
